ProShares Ultra NASDAQ Biotechnology
40 hedge funds and large institutions have $29M invested in ProShares Ultra NASDAQ Biotechnology in 2017 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 8 reducing their positions, and 6 closing their positions.
117% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 6
38% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 8
34% more capital invested
Capital invested by funds: $21.7M → $29M (+$7.31M)
21% more funds holding
Funds holding: 33 → 40 (+7)
2.16% more ownership
Funds ownership: 4.44% → 6.6% (+2.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
33% less call options, than puts
Call options by funds: $9.71M | Put options by funds: $14.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.13M |
| 2 |
VF
Virtu Financial
New York
|
+$2.91M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.71M |
| 4 |
PCA
Private Capital Advisors
Darien,
Connecticut
|
+$1.66M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$807K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
-$1.82M |
| 2 |
Simplex Trading
Chicago,
Illinois
|
-$384K |
| 3 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
-$251K |
| 4 |
LPL Financial
San Diego,
California
|
-$217K |
| 5 |
Koshinski Asset Management
Decatur,
Illinois
|
-$110K |
BIB Hedge Fund Activity: Q4 2017 in Review
40 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q4 2017, worth a combined $29M — up 34% from $21.7M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new BIB positions and 6 closed out — a net gain of 7 holders — while 11 added to existing stakes and 8 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $3.13M. The largest seller was Geneos Wealth Management, cutting an estimated $1.82M.
- 40 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q4 2017, up from 33 in Q3 2017.
- Funds reported $29M of ProShares Ultra NASDAQ Biotechnology stock for Q4 2017, up 34% quarter-over-quarter.
- 13 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q4 2017 and 6 closed out, a net change of +7 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q4 2017 was Susquehanna International Group, an estimated $3.13M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q4 2017 was Geneos Wealth Management, an estimated $1.82M sold.
Based on aggregated 13F filings for Q4 2017.